WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing

WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing

Client News

On April 10, 2019, Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as Inozyme’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.

Brian Johnson led the WilmerHale team representing Inozyme in this transaction which included Peter Roth and Andrea Sorrentino.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.